Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
third-generation EGFR-TKI + intrathecal pemetrexed
- Development stage
- Unknown
- Lead developer
- Fujian Medical University Cancer Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intrathecal
01
Overview
This combination therapeutic regimen is being evaluated by Fujian Cancer Hospital for the treatment of non-small cell lung cancer (NSCLC) patients who have developed leptomeningeal metastasis (LM) following progression on standard doses of third-generation EGFR tyrosine kinase inhibitors (TKIs). The regimen consists of a double dose of a third-generation EGFR-TKI (such as osimertinib, almonertinib, or furmonertinib) administered orally to enhance cerebrospinal fluid (CSF) penetration, combined with pemetrexed administered via intrathecal injection. This dual approach aims to overcome the blood-brain barrier limitations of systemic therapy by providing direct cytotoxic anti-folate activity within the leptomeninges while maintaining potent inhibition of mutated EGFR signaling.
- Other names
- Double Dose of Third-generation EGFR-TKI Plus Intrathecal PemetrexedDouble-dose 3rd-gen EGFR-TKI + Intrathecal PemetrexedThird-generation EGFR-TKI-Fujian Cancer Hospital-leptomeningeal metastasis
02
Targets
DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on third-generation EGFR-TKI + intrathecal pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on third-generation EGFR-TKI + intrathecal pemetrexed.